Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605561 | 0.91 | GPBAR1 (0.50) | GPBAR1BRD4HTR2CHTR2BHTR2A | |
| SCHEMBL15933941 | 0.82 | GPBAR1 (0.59) | GPBAR1BRD4NOTUM | |
| SCHEMBL8484580 | 0.78 | HTR2C (0.48) | GPBAR1HTR2CHTR2BHTR2A | |
| Trifluoroacetic Acid SCHEMBL6246336 | 0.77 | HTR2C (0.64) | HTR2CHTR2BHTR2ANOTUM | |
| SCHEMBL22588234 | 0.74 | GPR119 (0.50) | GPBAR1 | |
| SCHEMBL22605563 | 0.73 | HRH3 (0.47) | — | |
| SCHEMBL1908589 | 0.72 | NOTUM (0.53) | BRD4NOTUM | |
| SCHEMBL28533101 | 0.70 | GPBAR1 (0.39) | GPBAR1BRD4NOTUM | |
| SCHEMBL27988819 | 0.70 | GPBAR1 (0.54) | GPBAR1 | |
| Trifluoroacetic Acid SCHEMBL30124615 | 0.69 | KDM5A (0.40) | HTR2CHTR2ACACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | GPBAR1 3268/4885BRD4 257/4885HTR2C 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.